000			02092 a2200565 4500
005			20250513211333.0
264		0	_c20000601
008			200006s 0 0 eng d
022			_a0008-543X
024	7		_a10.1002/(sici)1097-0142(20000501)88:9<2037::aid-cncr8>3.0.co;2-k _2doi
040			_aNLM _beng _cNLM
100	1		_aSternberg, D W
245	0	0	_aTreatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen. _h[electronic resource]
260			_bCancer _cMay 2000
300			_a2037-41 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAdult
650	0	4	_aAge Factors
650	0	4	_aAged
650	0	4	_aAntimetabolites, Antineoplastic _xadministration & dosage
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aCause of Death
650	0	4	_aCerebellar Diseases _xchemically induced
650	0	4	_aCytarabine _xadministration & dosage
650	0	4	_aDeath, Sudden, Cardiac _xetiology
650	0	4	_aDisease-Free Survival
650	0	4	_aDrug Eruptions _xetiology
650	0	4	_aExanthema _xchemically induced
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInjections, Intravenous
650	0	4	_aLeukemia, Myeloid, Acute _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMitoxantrone _xadministration & dosage
650	0	4	_aNeoplasm Recurrence, Local _xdrug therapy
650	0	4	_aNeutropenia _xchemically induced
650	0	4	_aRemission Induction
650	0	4	_aThrombocytopenia _xchemically induced
650	0	4	_aTreatment Outcome
700	1		_aAird, W
700	1		_aNeuberg, D
700	1		_aThompson, L
700	1		_aMacNeill, K
700	1		_aAmrein, P
700	1		_aShulman, L N
773	0		_tCancer _gvol. 88 _gno. 9 _gp. 2037-41
856	4	0	_uhttps://doi.org/10.1002/(sici)1097-0142(20000501)88:9<2037::aid-cncr8>3.0.co;2-k _zAvailable from publisher's website
999			_c10765504 _d10765504